WO2006052660A3 - Il-7 receptor blockade to suppress immunity - Google Patents

Il-7 receptor blockade to suppress immunity Download PDF

Info

Publication number
WO2006052660A3
WO2006052660A3 PCT/US2005/039802 US2005039802W WO2006052660A3 WO 2006052660 A3 WO2006052660 A3 WO 2006052660A3 US 2005039802 W US2005039802 W US 2005039802W WO 2006052660 A3 WO2006052660 A3 WO 2006052660A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
interleukin
antagonist
receptor blockade
present
Prior art date
Application number
PCT/US2005/039802
Other languages
French (fr)
Other versions
WO2006052660A9 (en
WO2006052660A2 (en
Inventor
Kenneth Weinberg
Brile Chung
Original Assignee
Los Angeles Childrens Hospital
Kenneth Weinberg
Brile Chung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital, Kenneth Weinberg, Brile Chung filed Critical Los Angeles Childrens Hospital
Publication of WO2006052660A2 publication Critical patent/WO2006052660A2/en
Publication of WO2006052660A9 publication Critical patent/WO2006052660A9/en
Publication of WO2006052660A3 publication Critical patent/WO2006052660A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present application describes methods of suppressing an undesired immune response through the administration of an interleukin-7 antagonist to a subject in an amount effective to suppress the undesired immune response in the subject. A further aspect of the present invention describes a method of treating graft-versus-host disease in a mammalian subject through the administration of an interleukin-7 antagonist in an amount effective to treat the graft-versus-host disease in the subject. The present invention further describes the use of an interleukin-7 antagonist active agent for the preparation of a medicament for carrying out a method of treatment.
PCT/US2005/039802 2004-11-04 2005-11-04 Il-7 receptor blockade to suppress immunity WO2006052660A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62531804P 2004-11-04 2004-11-04
US60/625,318 2004-11-04

Publications (3)

Publication Number Publication Date
WO2006052660A2 WO2006052660A2 (en) 2006-05-18
WO2006052660A9 WO2006052660A9 (en) 2006-08-31
WO2006052660A3 true WO2006052660A3 (en) 2007-12-13

Family

ID=36337009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/039802 WO2006052660A2 (en) 2004-11-04 2005-11-04 Il-7 receptor blockade to suppress immunity

Country Status (1)

Country Link
WO (1) WO2006052660A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32038A (en) * 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd IMMUNOBLOBULINAS ANTI-CD127 AND ITS USES
EP2528947A4 (en) * 2010-01-28 2013-09-18 Glaxo Group Ltd Cd127 binding proteins
TWI596114B (en) 2010-02-24 2017-08-21 雷那特神經科學股份有限公司 Antagonist anti-il-7 receptor antibodies and methods
EP3294273A4 (en) * 2015-05-08 2018-12-05 Incube Labs, LLC Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
BR112021014106A2 (en) 2019-01-22 2021-10-13 Bristol-Myers Squibb Company ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain

Also Published As

Publication number Publication date
WO2006052660A9 (en) 2006-08-31
WO2006052660A2 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2010123569A3 (en) Immunonanotherapeutics providing a th1-biased response
UA86621C2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
WO2006055854A3 (en) Methods for reducing the side effects associated with mirtazapine treatment
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2005107726A3 (en) Method for the treatment of back pain
PH12013501341A1 (en) Morphinan compounds
NZ602510A (en) Treatment of lupus nephritis using laquinimod
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
SI1735278T1 (en) Histamine h3 receptor agents, preparation and therapeutic uses
SI1957484T1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
IN2012DN02782A (en)
WO2012033792A3 (en) Treatment of diseases
WO2018060463A3 (en) Treatment of prostate cancer
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
BRPI0921097A2 (en) pyrazol-3 carboxamide derivative compound with 5-ht2b receptor antagonist activity, preventive or therapeutic agent, pharmaceutical composition and use of the compound or pharmaceutically acceptable salt thereof and method or prevention or treatment.
WO2011085216A3 (en) Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
NZ601383A (en) Methods and compositions for improved nerve conduction velocity
WO2006052660A3 (en) Il-7 receptor blockade to suppress immunity
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05826266

Country of ref document: EP

Kind code of ref document: A2